The settlement concludes an eight-year investigation, during which investigators reviewed dumpster contents and found “hundreds of items” of hazardous waste and paper records containing patient health information.
Switzerland’s Silony Medical, which is buying the technology, sees itself as a challenger to “big medtech” in spinal fusion.
Centinel Spine to sell fusion business, focus on disc replacement Read More »
High inflation, labor shortages and industry consolidation contributed to the projected increase, according to a new survey of employers from consultancy Mercer.
Employers expect health benefit costs to climb 5.4% in 2024 Read More »
If the deal reported by Bloomberg solidifies, Walmart would be the latest retailer to snap up a value-based primary care chain for seniors, following in the footsteps of rivals CVS, Amazon and Walgreens.
Walmart reportedly exploring ChenMed acquisition Read More »
Zynex, Inc today announced that its board of directors approved a program to repurchase $10.0 million of the Company’s common stock.
Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system.
The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care.
Crinetics Aces Phase III in Rare Disease Acromegaly with Once-Daily Pill Read More »
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee.
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors Read More »
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA.
Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer.
